Cord Blood News Volume 12.15 | Apr 23 2020

TOP STORY

First-in-Human PeriCord Cardiac Bioimplant: Scalability and GMP Manufacturing of an Allogeneic Engineered Tissue Graft

The PeriCord is a clinical-size decellularised pericardial matrix colonized with human viable Wharton’s jelly-derived MSCs. PeriCord implantation was surgically performed on a large non-revascularisable scar in the inferior wall of a 63-year-old male patient. [EBioMedicine] Full Article

(Ranked by impact factor of the journal)

HSD11B1 Is Upregulated Synergistically by IFNγ and TNFα and Mediates TSG-6 Expression in Human UC-MSCs

Investigators found that glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), which converts inactive cortisone to the active cortisol and thereby regulates tissue glucocorticoid levels, was greatly upregulated by IFNγ and TNFα in human umbilical cord-derived MSCs in a synergistic manner. [Cell Death Discov] Full Article

Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplantation and Its Differences among Disease Risk or Types

Researchers assessed the effect of cytomegalovirus reactivation in adult single-unit cord blood transplantation without in vivo T cell depletion. There were 3,147 eligible cases including acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome. [Biol Blood Marrow Transplant] Abstract

Improving Cord Blood Typing with Next-Generation Sequencing: Impact of Allele-Level HLA and NIMA Determination on Their Selection for Transplantation

Scientists developed a cost-efficient high-resolution HLA typing strategy based on next-generation sequencing to improve the quality of the Barcelona Cord Blood Bank’s inventory, and investigated the impact of high-resolution HLA typing and NIMA determination on the preferential selection of cord blood for transplantation. [Bone Marrow Transplant] Abstract

Hematopoietic Cell Infusio-Related Adverse Events in Pediatric/Small Recipients in a Prospective/Multicenter Study

Whereas overall hematopoietic cell infusion-related adverse events rates did not differ among hematopoietic stem cell sources in the general recipients, bradycardia most often occurred after cord blood transplantation in whole small recipients. [Transfusion] Abstract

Nrf2 Modulates Immunosuppressive Ability and Cellular Senescence of Human Umbilical Cord Mesenchymal Stem Cells

Knock-down of Nrf2 in umbilical cord-derived MSCs induced premature senescence, decreased proliferation ability and immunosuppressive abilities. [Biochem Biophys Res Commun] Abstract

Intra-Articular Delivery of Umbilical Cord-Derived Mesenchymal Stem Cells Temporarily Retard the Progression of Osteoarthritis in a Rat Model

Single injection of human umbilical cord-derived MSCs had temporary effects on decelerating the progression of cartilage degeneration in osteoarthritis rats. [Int J Rheum Dis] Abstract

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications

Evidence, predominantly from pre-clinical in vitro and in vivo studies, suggests that MSC-extracellular vesicles may exhibit substantial therapeutic properties in many pathophysiological conditions, potentially restoring an extensive range of damaged or diseased tissues and organs. [Cells] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

US FDA Approves IMBRUVICA^® (Ibrutinib) plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of IMBRUVICA^® in combination with rituximab for the treatment of patients with CLL or small lymphocytic lymphoma who are new to therapy. [The Janssen Pharmaceutical Companies of Johnson & Johnson] Press Release

Allterum Therapeutics Closes $2.9 Million CPRIT Award to Develop Novel NCI Technology for Treating Pediatric Leukemia, Initiates Drug Manufacturing Scale-Up with Fujifilm Diosynth

Allterum Therapeutics, Inc. has closed on a $2.9 million Product Development award by the Cancer Research and Prevention Institute of Texas (CPRIT) to support preclinical development of its 4A10 antibody therapy for the treatment of pediatric patients suffering from T-cell acute lymphoblastic leukemia. [Allterum Therapeutics, Inc. (PR Newswire Assocation LLC)] Press Release

Untapped Potential: More US Labs Could Be Providing Tests for Coronavirus

A survey of more than 4,000 researchers in the United States suggests that better coordination at an institutional and national level could make hundreds of thousands more tests for coronavirus available. [Nature News] Editorial

How Research Funders Are Tackling Coronavirus Disruption

While science is crucial to the fight against COVID-19, researchers confined to their homes and unable to carry on with grant-funded work are becoming increasingly concerned about how the coronavirus pandemic will affect their funding. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Leukemia (Josep Carreras Leukaemia Research Institute)

Director – Blood Research Institute (Versiti)

Research Technician – Hematopoietic Stem Cells (Karolinska Institutet)

Postdoctoral Positions – Leukemia (Temple University School of Medicine)

Postdoctoral Position – Hematopoietic Stem Cells (Lund University)

Faculty Position – Regenerative Medicine (Guangzhou Regenerative Medicine and Health Guangdong Laboratory)

Postdoctoral Researcher – Hematologic Malignancies (Northwestern University)

Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Medical Center)

Postdoctoral Positions – Cancer Research (Moores Cancer Center, UC San Diego)

Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.